Evaluation of 153Sm/177Lu-EDTMP mixture in wild-type rodents as a novel combined palliative treatment of bone pain agent
- 129 Downloads
In this work, the cocktail complex 153Sm/177Lu-EDTMP was prepared in high radiochemical purity (more than 99 %) using in house synthesized EDTMP ligand for obtaining a possible synergistic wide range palliative agent. The mixture was administered to wild-type rats and biodistribution data collected after 2 h to 7 days showed at least 70 % accumulation of the radioactivity in the bone tissues. Scintigraphic images were taken from wild-type rats injected with 153Sm/177Lu-EDTMP after 24 h and the biodistribution was shown to be consistent with post-mortem data. A comparative accumulation study was performed for vital organs up to 7 days. 153Sm/177Lu-EDTMP seemed a promising agent for bone pain palliation therapy in skeletal metastases in humans as a novel combined radiopharmaceutical.
Keywords153Sm/177Lu-EDTMP Combined radiopharmaceutical Biodistribution Pain palliation Bone metastases
Authors wish to thank Tehran Research Reactor colleagues for their support and Mr. M. Mazidi for conducting animal studies.
Conflicts of interest
The authors report no conflicts of interest in this work.
- 3.Ayati N, Aryana K, Jalilian A, Hoseinnejad T, Bahrami Samani A, Ayati Z, Shariati F, Zakavi SR (2013) Treatment efficacy of 153Sm-EDTMP for painful bone metastasis. Asia Ocean J Nucl Med Biol 1:27–31Google Scholar
- 4.Beiki D, Fallahi B, Keyvan A (2013) Effectiveness and complications of 153Sm-EDTMP in palliative treatment of diffuse skeletal metastases. Iran J Nucl Med 21(1):26–32Google Scholar
- 5.Correa-González L, Arteaga de Murphy C, Pichardo-Romero P, Pedraza-López M, Moreno-García C, Correa-Hernández L (2014) 153Sm-EDTMP for pain relief of bone metastases from prostate and breast cancer and other malignancies. Arch Med Res (in press)Google Scholar
- 10.Zenda S, Nakagami Y, Toshima M, Arahira S, Kawashima M, Matsumoto Y, Kinoshita H, Satake M, Akimoto T (2013) Strontium-89 (Sr-89) chloride in the treatment of various cancer patients with multiple bone metastases. Int J Clin OncolGoogle Scholar
- 14.Lass P (2001) Radionuclide treatment of bone metastases—current concepts and trends. Nucl Med Rev Cent East Eur 4(1):1–3Google Scholar
- 20.Pandit-Taskar N, Batraki M, Divgi CR (2004) Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 45(8):1358–1365Google Scholar
- 22.Alavi MS (2010) Clinical trial project: Lu-177-EDTMP for Bone pain palliation of bone metastasis in breast cancer [Project]. Shiraz University of Medical Sciences, Nuclear Medicine CenterGoogle Scholar
- 24.Sola GAR, Arguelles MG, Bottazzini DL, Furnari JC, Parada IG, Rojo A, Ruiz HV (2000) Lutetium-177–EDTMP for bone pain palliation. Preparation, biodistribution and preclinical studies. Radiochim Acta 88:157–161Google Scholar
- 25.International Atomic Energy Agency (IAEA), VIENNA, Manual for reactor produced radioisotopes. IAEA-TECDOC-1340, ISBN 92-0-101103-2, ISSN 1011–4289, Austria, January 2003Google Scholar
- 27.EANM Radiopharmacy Committee (2007) Guidelines on current good radiopharmacy, practice (cGRPP) in the preparation of radiopharmaceuticals. Version 2. Comm Bruss 2:112–115Google Scholar
- 30.Bahrami-Samani A, Ghannadi-Maragheh M, Jalilian AR, Meftahi M, Shirvani-Arani S, Moradkhani S (2009) Production, quality control and biological evaluation of 153Sm-EDTMP in wild-type rodents. Iran J Nucl Med 17:12–19Google Scholar
- 32.Bahrami-Samani A, Anvari A, Jalilian AR, Shirvani-Arani S, Yousefnia H, Aghamiri MR, Ghannadi-Maragheh M (2012) Production, quality control and pharmacokinetic studies of 177Lu-EDTMP for human bone pain palliation therapy trials. Iran J Pharm Res 11(1):137–144Google Scholar